title: Recent technological updates and clinical applications of induced pluripotent stem cells.
abstract: Induced pluripotent stem cells (iPSCs) were first described in 2006 and have since emerged as a promising cell source for clinical applications. The rapid progression in iPSC technology is still ongoing and directed toward increasing the efficacy of iPSC production and reducing the immunogenic and tumorigenic potential of these cells. Enormous efforts have been made to apply iPSC-based technology in the clinic, for drug screening approaches and cell replacement therapy. Moreover, disease modeling using patient-specific iPSCs continues to expand our knowledge regarding the pathophysiology and prospective treatment of rare disorders. Furthermore, autologous stem cell therapy with patient-specific iPSCs shows great propensity for the minimization of immune reactions and the provision of a limitless supply of cells for transplantation. In this review, we discuss the recent updates in iPSC technology and the use of iPSCs in disease modeling and regenerative medicine.
authors.affiliation: Division of Cardiology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. ; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. ; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Diecke
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Seung Min
authors.initials: SM
authors.lastname: Jung
authors.affiliation: Division of Cardiology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. ; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. ; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Jaecheol
authors.initials: J
authors.lastname: Lee
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Ji Hyeon
authors.initials: JH
authors.lastname: Ju
mesh_terms: D000818:Animals; D065150:Cellular Reprogramming; D004353:Drug Evaluation, Preclinical; D018390:Gene Targeting; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology* / Q000637:transplantation*; D051379:Mice; D008954:Models, Biological; D044968:Regenerative Medicine
keywords: Disease model; Gene editing; Induced pluripotent stem cells; Regenerative medicine; Reprogramming technique